January 9, 2014 | Israeli pharmaceutical giant Teva Pharmaceutical Industries has made an offer to acquire American biotechnology company NuPathe for $149 million. NuPathe is developing treatments for various neurological disorders and has a market cap of $100 million.
Related posts
AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023
AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023
Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023
Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments